Planning an Effective In Vivo Study: Five Questions to Ask Before You Begin
An in vivo study should not begin simply because it’s on the Biologic Evaluation Plan, or it feels like the next step. It should begin because the project has reached a point where a specific question cannot be answered well enough through existing evidence, benchtop testing, in vitro methods, computational analysis, or another lower-burden approach.
This may mean clearing an FDA regulatory hurdle, advancing an early-phase Research and Development endpoint, or assessing factors too complex for static systems.
For medical devices (and pharmaceuticals), the best animal studies are not just technically sound—they are decision-ready. The study objective, model, endpoints, operations, and final report should all point to the same development decision.
1. What Decision Will This Study Support?
Before drafting the protocol, define the objective in plain language.
Ask yourself:
- Are you evaluating the body’s response at the point of contact or systemically?
- Are you evaluating human factors?
- Are you assessing device fixation or healing?
- Are you investigating device degradation or migration?
- Are you validating deployment?
- Are you addressing a risk identified during design review?
If the question is too broad, or too many questions are being answered at one time, the study often becomes unfocused. That can lead to endpoints that are difficult to interpret, data that does not support the submission strategy, or a study that must be repeated because it answered the wrong question.
2. Is an Animal Study Truly Necessary?
A well-developed plan explains why alternatives are not sufficient.
FDA guidance for device animal studies emphasizes use of animal studies when a suitable alternative is not available, but does not provide examples. Experienced guidance helps teams avoid default testing and build a more defensible rationale.
Answers should connect to the 3Rs: replacement, reduction, and refinement.
- Replacement – Can a non-animal approach answer the question?
- Reduction – How can valid information be obtained with the fewest animals necessary?
- Refinement – How can pain, distress, and unnecessary burden be minimized while preserving data quality?
3. Does the Model Fit the Device and Intended Use?
The correct animal model is not simply the model a team has used before or one called out in ISO 10993.
It should reflect:
- Anatomy
- Tissue interaction
- Procedural limits
- Exposure duration
- Biological response that matters for the device
For some products, scale and delivery matter most. For others, local tissue response or long-term healing may be the central question.
If the model is a compromise, the limitations should be named before the study starts so the data is not overinterpreted later.
4. Are the Endpoints Strong Enough to Carry the Data Story?
Endpoints should connect directly to the objective.
Useful endpoints may include:
- Clinical observations (“in-life data”)
- Notes from the surgical team
- Imaging
- Histopathology
- Changes to the test article
- Other explant analysis
The right endpoints depend on the risk being evaluated, and GLP studies should have all the endpoints spelled out clearly in advance.
A common oversight in study protocols is accounting for how to interpret data when things don’t go as planned.
The team should decide what the results will mean:
- What would support moving forward?
- What would trigger redesign?
- What would require additional testing?
- What would change the overall strategy?
An experienced Study Director can help clarify these in advance.
5. Is the Study Operationally Ready?
Many study problems are not scientific surprises; they are planning gaps.
Before initiation, confirm:
- Test article readiness
- Procedure staff are adequately trained
- The facility has the capabilities needed
- Analytical methods have been reviewed by additional expertise
- Pathology expectations are defined
- Reporting timelines are set
For submission-supporting work, determine whether the GLPs apply and whether the facility conducting the work has the experience needed to meet the protocol, records, quality oversight, and reporting endpoints required by the standard.
What Stronger Planning Makes Possible
A well-designed in vivo study is built before the first procedure begins.
The goal is not just to complete a study. The goal is to generate interpretable, defensible evidence that supports the next development decision without unnecessary animal use, avoidable delays, or costly rework.
Need Expert Guidance?
Need guidance on preclinical strategy, biological evaluation, or study planning?
Contact TEM Biomed to discuss your development program.
